Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Marius Distler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3164-5755; OpenAlex author ID A5020380620. Sources: OpenAlex.

Their work

Papers
30 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
66
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 4 papers · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 30

  1. Health-related quality of life among patients with colorectal und pancreatic cancer: results from a monocentric registry study. Co-author DOI 10.1055/a-2776-2703↗
  2. 17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing? Co-author DOI 10.1016/j.esmogo.2025.100218↗
  3. The Value of Blood T Cell Frequencies for Risk Prediction of Postoperative Complications in Pancreatic Cancer Surgery. Co-author DOI 10.1097/as9.0000000000000545↗
  4. Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a single center, retrospective trial. Co-author DOI 10.3389/fonc.2025.1602933↗
  5. Concomitant metastatic head-and-neck cancer and pancreatic cancer assessed by αvβ6-integrin PET/CT using 68Ga-Trivehexin: incidental detection of a brain metas… Co-author DOI 10.1007/s00259-024-06750-6↗
  6. αvβ6-integrin targeted PET/CT imaging in pancreatic cancer patients using 68Ga-Trivehexin. Co-author DOI 10.3389/fnume.2024.1487602↗
  7. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-0258↗
  8. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patient… Co-author DOI 10.1186/s13045-023-01404-w↗
  9. RAB27B expression in pancreatic cancer is predictive of poor survival but good response to chemotherapy. Co-author DOI 10.3233/cbm-220460↗
  10. VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer. Co-author DOI 10.3390/cancers15082326↗
  11. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. Co-author DOI 10.1002/path.5906↗
  12. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  13. [Ampullary Carcinoma-prognostic and Therapeutical Contrast to Pancreatic Ductal Adenocarcinoma]. Last author DOI 10.1055/a-1775-9024↗
  14. Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study. Co-author DOI 10.1186/s12885-022-09731-w↗
  15. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinica… First author DOI 10.1007/s00066-020-01654-4↗
  16. Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis. Co-author DOI 10.1007/s00423-021-02138-4↗
  17. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
  18. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Co-author DOI 10.1038/s41388-020-1186-7↗
  19. CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids. Co-author DOI 10.1155/2019/1024614↗
  20. Erratum to "CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids". Co-author DOI 10.1155/2019/9209764↗
  21. [Early stage pancreatic cancer]. First author DOI 10.1007/s00104-017-0569-y↗
  22. Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.05.005↗
  23. The "T" now Matters: The Eighth Edition of the Union for International Cancer Control Classification of Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002531↗
  24. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Co-author DOI 10.1136/gutjnl-2016-312432↗
  25. Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection. Co-author DOI 10.1038/s41598-017-08165-w↗
  26. Impact of Intraoperative Re-resection to Achieve R0 Status on Survival in Patients With Pancreatic Cancer: A Single-center Experience With 483 Patients. Co-author DOI 10.1097/sla.0000000000001808↗
  27. Top-down approach to the superior mesenteric artery and the mesopancreas during pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/jso.24204↗
  28. Impact of Portal Vein Involvement from Pancreatic Cancer on Metastatic Pattern After Surgical Resection. Co-author DOI 10.1245/s10434-016-5515-6↗
  29. Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. Co-author DOI 10.1155/2014/474905↗
  30. [New aspects of surgery for pancreatic cancer. Principles, results and evidence]. Co-author DOI 10.1007/s00292-012-1639-z↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jürgen Weitz · 20 shared papers, 2014–2025 · strength 2.53
  2. Sebastian Hempel · 8 shared papers, 2016–2026 · strength 1.49
  3. Thilo Welsch · 12 shared papers, 2016–2022 · strength 1.06
  4. Lena Seifert · 6 shared papers, 2020–2025 · strength 1.02
  5. Florian Oehme · 4 shared papers, 2023–2026 · strength 0.89
  6. Adrian M. Seifert · 6 shared papers, 2018–2025 · strength 0.88
  7. Max Heiduk · 4 shared papers, 2020–2025 · strength 0.65
  8. Robert Grützmann · 7 shared papers, 2012–2022 · strength 0.63
  9. Christoph Kahlert · 5 shared papers, 2018–2023 · strength 0.61
  10. David Digomann · 3 shared papers, 2023–2025 · strength 0.55
  11. Christian P. Pilarsky · 5 shared papers, 2014–2023 · strength 0.46
  12. Jörg Kotzerke · 2 shared papers, 2024 · strength 0.46
  13. Johannes Notni · 2 shared papers, 2024 · strength 0.46
  14. Jana Rehm · 2 shared papers, 2024 · strength 0.46
  15. Jochen M. Schmitt · 2 shared papers, 2022–2026 · strength 0.40
  16. Christoph Reißfelder · 4 shared papers, 2017–2022 · strength 0.38
  17. Christian Teske · 2 shared papers, 2021–2025 · strength 0.36
  18. Mathieu Pecqueux · 2 shared papers, 2023 · strength 0.31
  19. Franziska Baenke · 2 shared papers, 2022–2023 · strength 0.29
  20. Alexander Hennig · 3 shared papers, 2019–2022 · strength 0.28
  21. Daniel E. Stange · 3 shared papers, 2019–2022 · strength 0.28
  22. Frank Ulrich Weiß · 3 shared papers, 2018–2022 · strength 0.27
  23. Julia V. Mayerle · 3 shared papers, 2018–2022 · strength 0.27
  24. Markus M. Lerch · 3 shared papers, 2018–2022 · strength 0.27
  25. Ujjwal Mukund Mahajan · 3 shared papers, 2018–2022 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.